Axitinib
Overview
Axitinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors, used primarily in the treatment of renal cell carcinoma. Its ability to inhibit angiogenesis makes it an effective therapy for certain types of cancer.
API suppliers (4)
Suppliers of Axitinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
1 of 4 holds a GMP certificate on record in the EU or UK registers
- Apotex Inc.Canada1 active DMF
- SHILPA PHARMA LIFESCIENCES LTDIndia1 active DMF
- SynthonNetherlands1 active DMF GMP on record
- Wisdom Pharmaceutical Co., LtdChina1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Axitinib expires 12 Jul 2037. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Axitinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.